KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Total Non-Current Liabilities (2017 - 2025)

Aquestive Therapeutics has reported Total Non-Current Liabilities over the past 9 years, most recently at $186.8 million for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $186.8 million for Q4 2025, up 17.36% from a year ago — trailing twelve months through Dec 2025 was $186.8 million (up 17.36% YoY), and the annual figure for FY2025 was $186.8 million, up 17.36%.
  • Total Non-Current Liabilities for Q4 2025 was $186.8 million at Aquestive Therapeutics, up from $165.6 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for AQST hit a ceiling of $186.8 million in Q4 2025 and a floor of $112.0 million in Q1 2021.
  • Median Total Non-Current Liabilities over the past 5 years was $159.8 million (2023), compared with a mean of $154.1 million.
  • Biggest five-year swings in Total Non-Current Liabilities: soared 44.9% in 2021 and later fell 6.74% in 2023.
  • Aquestive Therapeutics' Total Non-Current Liabilities stood at $141.6 million in 2021, then rose by 22.56% to $173.6 million in 2022, then decreased by 6.74% to $161.9 million in 2023, then decreased by 1.67% to $159.2 million in 2024, then increased by 17.36% to $186.8 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $186.8 million (Q4 2025), $165.6 million (Q3 2025), and $164.2 million (Q2 2025) per Business Quant data.